Atrium Therapeutics has officially launched as a newly independent, publicly traded company with approximately USD 270 million in capital to advance novel RNA medicines for rare genetic cardiomyopathies. The company was established in connection with Novartis AG's acquisition of Avidity Biosciences, inheriting a targeted RNA delivery platform designed to deliver therapeutics directly to the heart.

Atrium's lead pipeline includes ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both of which are severe, life-threatening conditions with no approved therapies. The company expects to file Investigational New Drug (IND) applications for these candidates in H2 2026 and 2027, respectively, aiming to address the underlying cause of these genetic diseases.

The company's proprietary technology platform combines the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotides, enabling non-viral delivery of small interfering RNA (siRNA) to overcome challenges associated with non-specific tissue delivery.

PharmCube's NextBiopharm® database lists a total of 35 companies with active antibody-oligonucleotide conjugate projects globally, within which Atrium boasts the fifth-largest portfolio. Click here to request a free trial for NextBiopharm®.